BGBurcin Gungor

Burcin Gungor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Burcin Gungor has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diatom incorporated electrospun nanofibers for cell adhesion

    by Sultan Sacide Gelen, Bahar Aslanbay Guler, Zulal Sevgi Dede, Burcin Gungor, Simge Er Zeybekler, Esra Imamoglu, Dilek Odaci

  • Open Access

    Organ on a Chip

    by Burcin Gungor, Pakize Canturk, Sumeyye Idil Celikkaya, Bekir Caglar Celikkaya, John A Parkinson

    Traditional drug development methods have relied on 2D cell cultures and animal models, which have not been able to adequately represent human biology. Due to genetic and physiological variances in human biology, animal models cannot yield accurate results, whereas 2D cell cultures are insufficient in simulating tissue architecture and cell-to-cell interactions. These limitations have led to the development of organoid technology, which is made from stem cells and imitates the three-dimensional structure of organs. Organoids offer a strong platform for drug testing, disease mechanism modeling, and the creation of individualized treatment plans, but they have drawbacks, including long-term stability and microenvironment control. By incorporating organoids onto microchips, organ-on-a-chip technology has been created, improving biological realism and allowing us to evaluate pharmacological effects more precisely. Organ-on-chip technology replicates the microphysiological characteristics of organs on a chip by using bioengineering methods and microfluidic devices. The study of cancer is among the most notable applications of this technology. By accurately simulating the tumor microenvironment and the interactions between cancer cells and their surroundings, cancer-on-a-chip models help us comprehend the intricate nature of cancer biology. They thus offer a potent platform for the creation of fresh approaches to treatment as well as the assessment of the efficacy of current ones. These models can be used to precisely and thoroughly examine the efficacy of treatment regimens and drug combinations, especially for aggressive disease types like glioblastoma and breast cancer. Organ-on-chip technologies have revolutionary promise for advancing tailored treatment plans, understanding the mechanisms underlying complicated diseases like cancer, and speeding up medication development. These creative methods are ground-breaking instruments that will influence contemporary medicine and improve human health in the future.

  • Open Access

    Synthesis and Biological Evaluation of Novel N-Substituted 3-Methylindole Derivatives

    by Rawan Albhaisi, Dilruba Tirpanlar, Hulya Akgun, Burcin Gungor

  • Open Access

    Evaluation of the Interactions of Cabozantinib with Topoisomerase Enzymes by in vitro Enzyme Activity Assays, and its Effects on Cancer Cell Proliferation

    by Feyza Oflaz, Naz Ünal, Burcin Gungor, Pakize Cantürk

    The discovery of many drugs in recent years provides a definitive solution in the treatment of various diseases, but today, despite the discovery of many effective anticancer drugs, there are various types of cancer that have limitations in treatment and are still not completely curable. Since most of these limitations are due to cancer cells gaining resistance or compounds only being effective in certain types of cancer cells, the search for more effective anticancer drugs that are also effective in these types of cancer is inevitable. Cabozantinib is in medical use as a highly effective anticancer drug in various types of cancer, such as medullary thyroid cancer and kidney cancer. The anticancer properties of the Cabozantinib compound have attracted more attention in recent years, however, more studies are needed to define the anticancer activities of this compound. In our study, the interactions of Cabozantinib with topoisomerase enzymes, were demonstrated through in vitro enzyme activity tests, and the anti-proliferative effect of Cabozantinib was studied on MCF7, A549 and PC3 cell lines. By analyzing the interactions of the Cabozantinib with topoisomerases, the action mechanisms of the compound at the molecular level was evaluated.

  • Open Access

    Evaluation of the Anticancer and Biological Activities of Istaroxime via Ex Vivo Analyses, Molecular Docking and Conceptual Density Functional Theory Computations

    by Ege Gok, Naz Unal, Burcin Gungor, Gulderen Karakus, Savas Kaya, Pakize Canturk, Konstantin P. Katin

    Cancer is a disease that occurs as a result of abnormal or uncontrolled growth of cells due to DNA damage, among many other causes. Certain cancer treatments aim to increase the excess of DNA breaks to such an extent that they cannot escape from the general mechanism of cell checkpoints, leading to the apoptosis of mutant cells. In this study, one of the Sarco-endoplasmic reticulum Ca2+ATPase (SERCA2a) inhibitors, Istaroxime, was investigated. There has been very limited number of articles so far reporting Istaroxime’s anticancer activity; thus, we aimed to evaluate the anticancer effects of Istaroxime by cell proliferation assay and revealed the cytotoxic activity of the compound. We further determined the interaction of Istaroxime with topoisomerase enzymes through enzyme activity tests and detailed molecular modeling analysis. Istaroxime exhibited an antiproliferative effect on A549, MCF7, and PC3 cell lines and inhibited Topoisomerase I, suggesting that Istaroxime can act as a Topoisomerase I inhibitor under in vitro conditions. Molecular docking analysis supported the experimental observations. A chemical reactivity analysis of the Istaroxime molecule was made in the light of Density Functional Theory computations. For this aim, important chemical reactivity descriptors such as hardness, electronegativity, and electrophilicity were computed and discussed as detailed.


  • Open Access

    HSP70 induces liver X receptor pathway activation and cholesterol reduction in vitro and in vivo

    by Burcin Gungor, Lauri Vanharanta, Maarit Hölttä-Vuori, Juho Pirhonen, Nikolaj H.T. Petersen, Silvia Gramolelli, Päivi M. Ojala, Thomas Kirkegaard, Elina Ikonen


  • Open Access

    Concerted regulation of npc2 binding to endosomal/lysosomal membranes by bis(monoacylglycero)phosphate and sphingomyelin

    by Giray Enkavi, Heikki Mikkolainen, Burçin Güngör, Elina Ikonen, Ilpo Vattulainen

    Niemann-Pick Protein C2 (npc2) is a small soluble protein critical for cholesterol transport within and from the lysosome and the late endosome. Intriguingly, npc2-mediated cholesterol transport has been shown to be modulated by lipids, yet the molecular mechanism of npc2-membrane interactions has remained elusive. Here, based on an extensive set of atomistic simulations and free energy calculations, we clarify the mechanism and energetics of npc2-membrane binding and characterize the roles of physiologically relevant key lipids associated with the binding process. Our results capture in atomistic detail two competitively favorable membrane binding orientations of npc2 with a low interconversion barrier. The first binding mode (Prone) places the cholesterol binding pocket in direct contact with the membrane and is characterized by membrane insertion of a loop (V59-M60-G61-I62-P63-V64-P65). This mode is associated with cholesterol uptake and release. On the other hand, the second mode (Supine) places the cholesterol binding pocket away from the membrane surface, but has overall higher membrane binding affinity. We determined that bis(monoacylglycero)phosphate (bmp) is specifically required for strong membrane binding in Prone mode, and that it cannot be substituted by other anionic lipids. Meanwhile, sphingomyelin counteracts bmp by hindering Prone mode without affecting Supine mode. Our results provide concrete evidence that lipids modulate npc2-mediated cholesterol transport either by favoring or disfavoring Prone mode and that they impose this by modulating the accessibility of bmp for interacting with npc2. Overall, we provide a mechanism by which npc2-mediated cholesterol transport is controlled by the membrane composition and how npc2-lipid interactions can regulate the transport rate. Cholesterol plays essential structural and functional roles in all vertebrate cells. Abnormalities in cholesterol metabolism are associated with severe and wide-spread diseases. Cholesterol efflux is one of the essential steps in its metabolism and is mediated by Niemann-Pick Protein C2 (npc2) in endosomes and lysosomes. Mutations in npc2 result in the fatal genetic disease, called Niemann-Pick C disease, characterized by neuronal degeneration resulting in early death. We performed an extensive set of atomistic molecular dynamics simulations employing enhanced sampling approaches to investigate how npc2 mediates cholesterol transport and the roles of membrane lipids in the process. We show that the binding of npc2 to endosomal/lysosomal membranes and the consequent trafficking of cholesterol are concertedly regulated by bis(monoacylglycero)phosphate and sphingomyelin. Moreover, our results explain the molecular mechanism of experimentally observed affect of lipids on cholesterol transport rate. In essence, our findings provide key insights into the regulation of the lysosomal and endosomal cholesterol trafficking by npc2 and reveal key lipid-protein interactions.


  • Open Access

    Plasma membranes as heat stress sensors: From lipid-controlled molecular switches to therapeutic applications

    by Zsolt Török, Tim Crul, Bruno Maresca, Gerhard J. Schütz, Felix Viana, Laura Dindia, Stefano Piotto, Mario Brameshuber, Gábor Balogh, Mária Péter, et al.


  • Open Access

    Rac1 Participates in Thermally Induced Alterations of the Cytoskeleton, Cell Morphology and Lipid Rafts, and Regulates the Expression of Heat Shock Proteins in B16F10 Melanoma Cells

    by Burcin Gungor, Imre Gombos, Tim Crul, Ferhan Ayaydin, László Szabó, Zsolt Török, Lajos Mátés, László Vígh, Ibolya Horváth

    Eukaryotic cells exhibit a characteristic response to hyperthermic treatment, involving morphological and cytoskeletal alterations and the induction of heat shock protein synthesis. Small GTPases of the Ras superfamily are known to serve as molecular switches which mediate responses to extracellular stimuli. We addressed here how small GTPase Rac1 integrates signals from heat stress and simultaneously induces various cellular changes in mammalian cells. As evidence that Rac1 is implicated in the heat shock response, we first demonstrated that both mild (41.5°C) and severe (43°C) heat shock induced membrane translocation of Rac1. Following inhibition of the activation or palmitoylation of Rac1, the size of its plasma membrane-bound pool was significantly decreased while the heat shock-induced alterations in the cytoskeleton and cell morphology were prevented. We earlier documented that the size distribution pattern of cholesterol-rich rafts is temperature dependent and hypothesized that this is coupled to the triggering mechanism of stress sensing and signaling. Interestingly, when plasma membrane localization of Rac1 was inhibited, a different and temperature independent average domain size was detected. In addition, inhibition of the activation or palmitoylation of Rac1 resulted in a strongly decreased expression of the genes of major heat shock proteins hsp25 and hsp70 under both mild and severe heat stress conditions.


  • Membrane fluidity matters: Hyperthermia from the aspects of lipids and membranes

    by Balint Csoboz, Gabor E. Balogh, Erzsebet Kusz, Imre Gombos, Maria Peter, Tim Crul, Burcin Gungor, Lajos Haracska, Gordana Bogdanovics, Zsolt Torok, et al.

    Hyperthermia is a promising treatment modality for cancer in combination both with radio- and chemotherapy. In spite of its great therapeutic potential, the underlying molecular mechanisms still remain to be clarified. Due to lipid imbalances and ‘membrane defects’ most of the tumour cells possess elevated membrane fluidity. However, further increasing membrane fluidity to sensitise to chemo- or radiotherapy could have some other effects. In fact, hyperfluidisation of cell membrane induced by membrane fluidiser initiates a stress response as the heat shock protein response, which may modulate positively or negatively apoptotic cell death. Overviewing some recent findings based on a technology allowing direct imaging of lipid rafts in live cells and lipidomics, novel aspects of the intimate relationship between the ‘membrane stress’ of tumour cells and the cellular heat shock response will be highlighted. Our findings lend support to both the importance of membrane remodelling and the release of lipid signals initiating stress protein response, which can operate in tandem to control the extent of the ultimate cellular thermosensitivity. Overall, we suggest that the fluidity variable of membranes should be used as an independent factor for predicting the efficacy of combinational cancer therapies.